Movatterモバイル変換


[0]ホーム

URL:


NO20005913L - Legemiddelsammensetning - Google Patents

Legemiddelsammensetning

Info

Publication number
NO20005913L
NO20005913LNO20005913ANO20005913ANO20005913LNO 20005913 LNO20005913 LNO 20005913LNO 20005913 ANO20005913 ANO 20005913ANO 20005913 ANO20005913 ANO 20005913ANO 20005913 LNO20005913 LNO 20005913L
Authority
NO
Norway
Prior art keywords
medicinal composition
medicinal
composition
Prior art date
Application number
NO20005913A
Other languages
English (en)
Other versions
NO20005913D0 (no
Inventor
Hiroshi Susaki
Kazuhiro Inoue
Hiroshi Kuga
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku CofiledCriticalDaiichi Seiyaku Co
Publication of NO20005913D0publicationCriticalpatent/NO20005913D0/no
Publication of NO20005913LpublicationCriticalpatent/NO20005913L/no

Links

Classifications

Landscapes

NO20005913A1998-05-222000-11-22LegemiddelsammensetningNO20005913L (no)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
JP140915981998-05-22
PCT/JP1999/002681WO1999061061A1 (fr)1998-05-221999-05-21Composites medicamenteux

Publications (2)

Publication NumberPublication Date
NO20005913D0 NO20005913D0 (no)2000-11-22
NO20005913Ltrue NO20005913L (no)2001-01-22

Family

ID=15279786

Family Applications (1)

Application NumberTitlePriority DateFiling Date
NO20005913ANO20005913L (no)1998-05-222000-11-22Legemiddelsammensetning

Country Status (12)

CountryLink
US (1)US6835807B1 (no)
EP (1)EP1080732A4 (no)
JP (1)JP4560210B2 (no)
KR (1)KR100581443B1 (no)
CN (1)CN1250293C (no)
AU (1)AU3733399A (no)
CA (1)CA2333321A1 (no)
EA (1)EA003398B1 (no)
HK (1)HK1040052B (no)
NO (1)NO20005913L (no)
TW (1)TWI253935B (no)
WO (1)WO1999061061A1 (no)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
TW527183B (en)1996-06-062003-04-11Daiichi Seiyaku CoDrug complex
WO2000025825A1 (fr)*1998-10-302000-05-11Daiichi Pharmaceutical Co., Ltd.Composes dds et procede de dosage de ces composes
AU2001267831A1 (en)*2000-06-292002-01-08Daiichi Pharmaceutical Co., Ltd.DDS compound and process for the preparation thereof
TWI313609B (en)*2001-08-212009-08-21Mitsubishi Tanabe Pharma CorpPharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
JP4959136B2 (ja)*2002-12-132012-06-20イミューノメディクス、インコーポレイテッド細胞内で開裂可能な結合を有する免疫接合体
US7282590B2 (en)*2004-02-122007-10-16The Research Foundation Of State University Of New YorkDrug conjugates
WO2005082023A2 (en)2004-02-232005-09-09Genentech, Inc.Heterocyclic self-immolative linkers and conjugates
WO2007083984A1 (en)*2006-01-232007-07-26Gwangju Institute Of Science And TechnologyConjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
CN1973902B (zh)*2006-12-122010-11-10东北师范大学以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
CN102014966B (zh)*2008-04-222013-11-27费迪亚医药股份公司含有与透明质酸结合的抗肿瘤药物的新药物制剂在治疗瘤形成中的治疗性应用
EP2662095A1 (en)2010-04-152013-11-13Spirogen SàrlPyrrolobenzodiazepines and conjugates thereof
CN107141410B (zh)2010-05-252022-12-09辛德弗雷克斯公司聚合物缀合的MetAP2抑制剂及其应用的治疗方法
US9895449B2 (en)2010-05-252018-02-20Syndevrx, Inc.Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
HUE025661T2 (en)2011-10-142016-04-28Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
KR102052774B1 (ko)2011-11-042019-12-04자임워크스 인코포레이티드Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
WO2013177481A1 (en)2012-05-252013-11-28Immunogen, Inc.Benzodiazepines and conjugates thereof
BR122021014396B1 (pt)*2012-10-112022-07-05Daiichi Sankyo Company, LimitedCompostos intermediários ligantes de fármacos, e ligante
SMT201900017T1 (it)2012-10-122019-02-28Medimmune LtdConiugati pirrolobenzodiazepina-anticorpo
TR201808051T4 (tr)2012-10-122018-06-21Adc Therapeutics SaPirrolobenzodiazepin antikor konjugatları.
ES2660029T3 (es)2012-10-122018-03-20Medimmune LimitedConjugados de anticuerpo-pirrolobenzodiazepinas
PT2766048E (pt)2012-10-122015-02-25Spirogen SarlPirrolobenzodiazepinas e conjugados das mesmas
WO2014057114A1 (en)2012-10-122014-04-17Adc Therapeutics SàrlPyrrolobenzodiazepine-anti-psma antibody conjugates
DK2906253T3 (en)2012-10-122018-10-22Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
DK2906251T3 (da)2012-10-122017-11-20Adc Therapeutics SaPyrrolobenzodiazepin-anti-CD22-antistofkonjugater
ES2782248T3 (es)*2012-10-192020-09-11Daiichi Sankyo Co LtdConjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
EA032986B1 (ru)2012-12-212019-08-30Медимьюн ЛимитедПирролобензодиазепины
AU2013366493B2 (en)2012-12-212017-08-24Medimmune LimitedPyrrolobenzodiazepines and conjugates thereof
ES2731779T3 (es)2013-03-132019-11-19Medimmune LtdPirrolobenzodiazepinas y conjugados de las mismas
CN105307685B (zh)2013-03-132019-03-08麦迪穆有限责任公司吡咯并苯并二氮杂卓和其结合物
CA2905181C (en)2013-03-132020-06-02Medimmune LimitedPyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
ES2749746T3 (es)2013-04-102020-03-23Syndevrx IncInhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
WO2015052534A1 (en)2013-10-112015-04-16Spirogen SàrlPyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en)2013-10-112018-07-03Medimmune LimitedPyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en)2013-10-112013-11-27Spirogen SarlPyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en)2013-10-112015-04-16Spirogen SàrlPyrrolobenzodiazepine-antibody conjugates
KR102535900B1 (ko)2013-12-252023-05-26다이이찌 산쿄 가부시키가이샤항 trop2 항체-약물 컨쥬게이트
PH12020552271A1 (en)2014-01-312022-05-02Daiichi Sankyo Co LtdAnti-her2 antibody-drug conjugate
EP3125943A4 (en)2014-04-042017-12-06Merck Sharp & Dohme Corp.Phosphate based linkers for intracellular delivery of drug conjugates
JP6105171B2 (ja)2014-04-102017-03-29第一三共株式会社抗her3抗体−薬物コンジュゲート
WO2015155976A1 (ja)2014-04-102015-10-15第一三共株式会社抗her2抗体-薬物コンジュゲート
GB201406767D0 (en)2014-04-152014-05-28Cancer Rec Tech LtdHumanized anti-Tn-MUC1 antibodies anf their conjugates
CN106687141A (zh)2014-09-102017-05-17麦迪穆有限责任公司吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en)2014-09-122014-10-29Medimmune LtdPyrrolobenzodiazepines and conjugates thereof
BR112017011111A2 (pt)2014-11-252017-12-26Adc Therapeutics Saconjugados de pirrolobenzodiazepina-anticorpo
WO2016164916A1 (en)2015-04-102016-10-13Thomas Jefferson UniversityMethods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
GB201506402D0 (en)2015-04-152015-05-27Berkel Patricius H C Van And Howard Philip WSite-specific antibody-drug conjugates
GB201506411D0 (en)2015-04-152015-05-27Bergenbio AsHumanized anti-axl antibodies
GB201506389D0 (en)2015-04-152015-05-27Berkel Patricius H C Van And Howard Philip WSite-specific antibody-drug conjugates
EP3315512B1 (en)2015-06-292022-11-23Daiichi Sankyo Co., Ltd.Method for selectively manufacturing antibody-drug conjugate
WO2017062334A1 (en)2015-10-052017-04-13Merck Sharp & Dohme Corp.Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
EP3359194A4 (en)2015-10-062019-04-24Merck Sharp & Dohme Corp. ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
KR102849342B1 (ko)2015-12-102025-08-21신데브알엑스, 인크.푸마길롤 유도체 및 그의 다형체
WO2017123603A1 (en)2016-01-112017-07-20Syndevrx, Inc.Treatment for tumors driven by metabolic dysfunction
GB201601431D0 (en)2016-01-262016-03-09Medimmune LtdPyrrolobenzodiazepines
EP3407916B1 (en)2016-01-292023-12-20Merck Sharp & Dohme LLCPhosphonate linkers and their use to facilitate cellular retention of compounds
GB201602359D0 (en)2016-02-102016-03-23Medimmune LtdPyrrolobenzodiazepine Conjugates
GB201602356D0 (en)2016-02-102016-03-23Medimmune LtdPyrrolobenzodiazepine Conjugates
GB201607478D0 (en)2016-04-292016-06-15Medimmune LtdPyrrolobenzodiazepine Conjugates
GB201617466D0 (en)2016-10-142016-11-30Medimmune LtdPyrrolobenzodiazepine conjugates
TWI862473B (zh)2016-12-122024-11-21日商第一三共股份有限公司抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
TWI780104B (zh)2017-01-172022-10-11日商第一三共股份有限公司抗gpr20抗體及抗gpr20抗體-藥物結合物、以及其製造方法及用途
GB201702031D0 (en)2017-02-082017-03-22Medlmmune LtdPyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (da)2017-02-082021-05-10Adc Therapeutics SaPyrrolobenzodiazepin-antistof-konjugater
SI3612537T1 (sl)2017-04-182022-10-28Medimmune LimitedKonjugati pirolobenzodiazepina
US20200129637A1 (en)2017-04-202020-04-30Adc Therapeutics SaCombination therapy with an anti-axl antibody-drug conjugate
TW202504644A (zh)2017-05-152025-02-01日商第一三共股份有限公司抗體-藥物結合物之用途
WO2018229222A1 (en)2017-06-142018-12-20Adc Therapeutics SaDosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (ko)2017-08-182021-06-30메디뮨 리미티드피롤로벤조디아제핀 컨쥬게이트
IL272964B2 (en)2017-08-312024-02-01Daiichi Sankyo Co LtdMethod for producing antibody-drug conjugate
BR112020003646A2 (pt)2017-08-312020-09-01Daiichi Sankyo Company, Limitedcristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
EP3700540A4 (en)2017-10-242021-11-10Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
CN119857155A (zh)2017-11-292025-04-22海德堡医药研究有限责任公司用于耗尽cd5+细胞的组合物和方法
GB201803342D0 (en)2018-03-012018-04-18Medimmune LtdMethods
GB201806022D0 (en)2018-04-122018-05-30Medimmune LtdPyrrolobenzodiazepines and conjugates thereof
TWI839357B (zh)2018-05-182024-04-21日商第一三共股份有限公司抗muc1抗體藥物複合體
CA3107383A1 (en)2018-07-232020-01-30Magenta Therapeutics, Inc.Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
JP7406488B2 (ja)2018-07-272023-12-27第一三共株式会社抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
EA202190403A1 (ru)2018-07-312021-05-24Дайити Санкио Компани, ЛимитедЛечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
WO2020087077A1 (en)2018-10-262020-04-30Syndevrx,Inc.Biomarkers of metap2 inhibitors and applications thereof
ES2967878T3 (es)2019-03-152024-05-06Medimmune LtdDímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
CN114174317A (zh)2019-04-242022-03-11海德堡医药研究有限责任公司鹅膏毒素抗体-药物缀合物及其用途
GB201908128D0 (en)2019-06-072019-07-24Adc Therapeutics SaPyrrolobenzodiazepine-antibody conjugates
CN110339181A (zh)*2019-07-022019-10-18中国药科大学一种基于点击反应的pH响应型纳米制剂及其制法和应用
AU2020311925A1 (en)2019-07-102022-02-03Cybrexa 3, Inc.Peptide conjugates of microtubule-targeting agents as therapeutics
PE20220563A1 (es)2019-07-102022-04-13Cybrexa 2 IncConjugados peptidicos de citotoxinas como terapeuticos
CA3160557A1 (en)*2020-01-312021-08-05Innate PharmaTreatment of cancer
WO2022043256A1 (en)2020-08-232022-03-03Cobiores NvSynergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents
CN116199739B (zh)*2020-09-302024-12-17映恩生物制药(苏州)有限公司一种抗肿瘤化合物及其制备方法和应用
AU2021387795A1 (en)2020-11-252023-06-01Innate PharmaTreatment of cancer
WO2022136586A1 (en)2020-12-222022-06-30Cobiores NvCompounds comprising a tetrapeptidic moiety
WO2022167664A1 (en)2021-02-072022-08-11Cobiores NvCompounds comprising a tetrapeptidic moiety
US11806405B1 (en)2021-07-192023-11-07Zeno Management, Inc.Immunoconjugates and methods
US20230355792A1 (en)2022-04-072023-11-09Heidelberg Pharma Research GmbhMethods of improving the therapeutic index
EP4532020A1 (en)2022-05-252025-04-09Innate PharmaNectin-4 binding agents
WO2024121632A1 (en)2022-12-092024-06-13Crispr Therapeutics AgUse of anti-cd117 antibody drug conjugate (adc)
AU2024237541A1 (en)2023-03-132025-08-28Heidelberg Pharma Research GmbhSubcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0526649B1 (en)1991-02-211998-05-20Drug Delivery System Institute, Ltd.Carboxymethylmannoglucan and derivative thereof
JP3359955B2 (ja)*1992-07-162002-12-24第一製薬株式会社抗腫瘍剤
CA2134348C (en)1993-02-262007-01-02Hideo NogusaPolysaccharide derivatives and drug carriers
US6214345B1 (en)*1993-05-142001-04-10Bristol-Myers Squibb Co.Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0784481A (ja)1993-06-261995-03-31Ricoh Co Ltd画像形成装置
CA2192725C (en)*1995-12-282004-04-20Kenji TsujiharaCamptothecin derivatives
TW527183B (en)*1996-06-062003-04-11Daiichi Seiyaku CoDrug complex
TW409058B (en)*1996-06-062000-10-21Daiichi Seiyaku CoMethod for preparation of a drug complex
US6368598B1 (en)*1996-09-162002-04-09Jcrt Radiation Oncology Support Services, Inc.Drug complex for treatment of metastatic prostate cancer
AU739028B2 (en)1996-09-272001-10-04Bristol-Myers Squibb CompanyHydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998019705A1 (en)*1996-11-051998-05-14Bristol-Myers Squibb CompanyBranched peptide linkers
JPH1171280A (ja)1997-06-261999-03-16Tanabe Seiyaku Co Ltd医薬組成物
JPH1192405A (ja)1997-09-191999-04-06Dai Ichi Seiyaku Co Ltd薬物複合体
WO2000025825A1 (fr)*1998-10-302000-05-11Daiichi Pharmaceutical Co., Ltd.Composes dds et procede de dosage de ces composes

Also Published As

Publication numberPublication date
JP4560210B2 (ja)2010-10-13
KR100581443B1 (ko)2006-05-23
US6835807B1 (en)2004-12-28
HK1040052A1 (en)2002-05-24
CN1310631A (zh)2001-08-29
NO20005913D0 (no)2000-11-22
TWI253935B (en)2006-05-01
HK1040052B (zh)2006-09-15
CN1250293C (zh)2006-04-12
EP1080732A4 (en)2004-08-25
EP1080732A1 (en)2001-03-07
AU3733399A (en)1999-12-13
EA200001217A1 (ru)2001-06-25
KR20010052385A (ko)2001-06-25
CA2333321A1 (en)1999-12-02
WO1999061061A1 (fr)1999-12-02
EA003398B1 (ru)2003-04-24

Similar Documents

PublicationPublication DateTitle
NO20005913D0 (no)Legemiddelsammensetning
ID27415A (id)Komposisi farmaseutik
EA199900373A3 (ru)Фармацевтические композиции
ID26186A (id)Komposisi sampo
ID28694A (id)Komposisi sampo
ID26720A (id)Komposisi oral
ID29430A (id)Komposisi herbisida
ID29262A (id)Komposisi farmasi
ID20233A (id)Komposisi oral
NO20004758D0 (no)Vaksinesammensetning
NO992692D0 (no)Nefadozon doseringsform
ID27201A (id)Komposisi farmasi
DK1466615T3 (da)Farmaceutisk præparat
DE69928862D1 (de)Zusammensetzung
DE69942892D1 (de)Gaserzeugende zusammensetzung
DK1023035T3 (da)Mundplejemiddel
ID20466A (id)Komposisi oral
ID29294A (id)Komposisi farmasi
ID25857A (id)Komposisi farmasi
EP1124557A4 (en)Pharmaceutical composition
ID26295A (id)Komposisi keras-ultraviolet
ID26215A (id)Komposisi farmasi
ID26485A (id)Komposisi paroksetina
FI961364L (fi)Lääkeainekoostumus
ID28359A (id)Komposisi

Legal Events

DateCodeTitleDescription
FC2AWithdrawal, rejection or dismissal of laid open patent application

[8]ページ先頭

©2009-2025 Movatter.jp